Efficacy of TECAR Therapy in Patients With Knee Osteoarthritis
Launched by ANKARA CITY HOSPITAL BILKENT · May 13, 2024
Trial Information
Current as of March 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 3 months of conservative treatment for unresponsive knee pain
- • Kellgren-Lawrence grade 2-3 on radiographic evaluation
- • Agreed to participate in the study.
- Exclusion Criteria:
- • History of physical therapy (electrotherapy/exercise) in the past 3 months
- • Intra-articular injection therapy in the past 3 months,
- • History of surgery or trauma to the affected knee
- • Inflammatory or neurological disease affecting the lower extremities
- • Active vasculitis or severe peripheral vascular disease
- • Pregnancy or lactation
- • Diagnosed restless legs syndrome
- • Neoplasia
- • Local sensory impairment,
- • Local or systemic acute infections
- • Severe osteoporosis
- • Pacemaker
- • Psychiatric disorder and cognitive impairment.
About Ankara City Hospital Bilkent
Ankara City Hospital Bilkent is a leading healthcare institution in Turkey, dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals, the hospital fosters a collaborative environment for conducting rigorous scientific investigations. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the highest level of integrity, ultimately contributing to the development of new therapies and enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
